Wang X, Yang L, Kurtz L, Lichtin A, DeLeo V A, Bloomer J, Poh-Fitzpatrick M B
Department of Dermatology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
J Invest Dermatol. 1999 Jul;113(1):87-92. doi: 10.1046/j.1523-1747.1999.00637.x.
Ferrochelatase, the enzyme that catalyzes the terminal step in the heme biosynthetic pathway, is the site of the defect in the human inherited disease erythropoietic protoporphyria. Molecular genetic studies have shown that the majority of erythropoietic protoporphyria cases are transmitted in dominant fashion and that mutations underlying erythropoietic protoporphyria are heterogeneous. We performed haplotype analysis of American families that shared recurrent ferrochelatase gene mutations yet had forbearers from several European countries. This was to gain insight into whether these mutations represent mutational hotspots at the ferrochelatase gene, or propagation of ancestral alleles bearing the mutations. Two recurrent mutations were found to occur on distinctive chromosome 18 haplotypes, consistent with being hotspot mutations. On the other hand, we found three sets of two unrelated families that shared the same haplotypes bearing these mutations, which could reflect geographic dispersion of ancestral mutant alleles. In addition, we report novel mutations associated with erythropoietic protoporphyria: g(+ 1)-->t transversion of the exon 4 donor site, g(+ 1)-->a transition of the exon 6 donor site, and t(+ 2)-->a substitution at the exon 9 donor site; these mutations are predicted to cause splicing defects of the associated exons. We also identified a g(+ 5)-->a transition of the exon 1 donor site in four unrelated families with erythropoietic protoporphyria, and a G(- 1)-->A substitution at the exon 9 donor site in an additional family. The probability that these sequence changes are normal polymorphisms was virtually excluded (p < 0.0001) by their absence in 120 ferrochelatase alleles from 30 normal subjects and 30 individuals with manifested erythropoietic protoporphyria with or without a known mutation.
亚铁螯合酶是催化血红素生物合成途径最后一步的酶,是人类遗传性疾病红细胞生成性原卟啉症的缺陷位点。分子遗传学研究表明,大多数红细胞生成性原卟啉症病例以显性方式遗传,且红细胞生成性原卟啉症的潜在突变具有异质性。我们对美国家庭进行了单倍型分析,这些家庭共享反复出现的亚铁螯合酶基因突变,但有来自几个欧洲国家的祖先。这样做是为了深入了解这些突变是代表亚铁螯合酶基因的突变热点,还是携带这些突变的祖先等位基因的传播。发现两个反复出现的突变发生在独特的18号染色体单倍型上,这与热点突变一致。另一方面,我们发现三组两个不相关的家庭共享携带这些突变的相同单倍型,这可能反映了祖先突变等位基因的地理分布。此外,我们报告了与红细胞生成性原卟啉症相关的新突变:外显子4供体位点的g(+1)-->t颠换、外显子6供体位点的g(+1)-->a转换以及外显子9供体位点的t(+2)-->a替换;这些突变预计会导致相关外显子的剪接缺陷。我们还在四个患有红细胞生成性原卟啉症的不相关家庭中鉴定出外显子1供体位点的g(+5)-->a转换,并在另一个家庭中鉴定出在外显子9供体位点的G(-1)-->A替换。30名正常受试者和30名患有或不患有已知突变的显性红细胞生成性原卟啉症患者的120个亚铁螯合酶等位基因中未出现这些序列变化,几乎排除了这些序列变化是正常多态性的可能性(p<0.0001)。